Anavex Life Sciences (NASDAQ: AVXL) schedules 2026 annual meeting and proposal deadlines
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Anavex Life Sciences Corp. scheduled its 2026 Annual Meeting of Stockholders for September 24, 2026. The Board of Directors set July 31, 2026 as the record date, determining which stockholders are entitled to receive notice of and vote at the meeting.
The company also set revised timing guidelines for stockholder proposals and director nominations because the 2026 meeting will occur more than 30 days after the prior year’s meeting. Proposals and nominations received on or before July 10, 2026 will be considered submitted within a reasonable time before proxy materials are printed and mailed.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
2026 Annual Meeting date: September 24, 2026
Record date: July 31, 2026
Proposal timing guideline: July 10, 2026
+1 more
4 metrics
2026 Annual Meeting date
September 24, 2026
Date set by Board of Directors
Record date
July 31, 2026
Determines stockholders entitled to vote
Proposal timing guideline
July 10, 2026
Considered a reasonable time before proxy printing
Company address
630 5th Avenue, 20th Floor, New York, NY 10111
Principal executive offices for proposal submissions
Key Terms
Annual Meeting of Stockholders, record date, Rule 14a-8, Rule 14a-5(f), +1 more
5 terms
Annual Meeting of Stockholders financial
"the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)"
record date financial
"July 31, 2026, as the record date for the determination of stockholders"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
Rule 14a-8 regulatory
"submitted for inclusion in the Company’s proxy materials pursuant to Rule 14a-8 under the Exchange Act"
Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.
Rule 14a-5(f) regulatory
"in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934"
proxy materials financial
"before the Company begins to print and send its proxy materials"
Proxy materials are the packet of documents sent to shareholders that explain items to be voted on at a company meeting and include the actual ballot or instructions for casting a vote. Think of them as a voting packet that lays out who’s running the company, major proposals (like pay, mergers, or board changes), and arguments for and against each item. Investors care because those votes shape corporate direction, affect risk and future profits, and can influence share value.
FAQ
What is the deadline for stockholder proposals for AVXL’s 2026 Annual Meeting?
Anavex Life Sciences will treat stockholder proposals received on or before July 10, 2026 as received within a reasonable time before proxy materials are printed. This timing applies to proposals submitted under Rule 14a-8 and those submitted outside that rule.
How can AVXL stockholders submit director nominations for the 2026 Annual Meeting?
Stockholders may submit director nominations to Anavex Life Sciences’ principal executive offices at 630 5th Avenue, 20th Floor, New York, NY 10111. Nominations received on or before July 10, 2026 will be considered timely for inclusion in the company’s proxy process.